Skip to main content
. 2014 Aug 5;111(6):1168–1179. doi: 10.1038/bjc.2014.421

Figure 5.

Figure 5

Combination of NVP-LDE225 and everolimus/sunitinib induces a cooperative antitumour effect in 786-O SuR tumour xenografts. (A–D) After 14 days following injection of 786-O SuR cells, mice were randomised (10 per group) to receive one daily administrations of NVP-LDE225, everolimus, sunitinib, or their combination for 3 weeks (as described in Materials and Methods section). The one-way ANOVA test was used to compare tumour sizes between the different treatment groups with respect to the median survival of the control group (24.5 days). The results were statistically significant for the combination treatment as opposed to single agents (P<0.001). (B–E) Median survival was statistically significant for the combinations vs control (P<0.001), as evaluated by long-rank test. (C–F) Western blot analysis on total lysates from 786-O SuR tumour specimens of two mice per group killed on day 35. Densitometric measurements were normalised to β-actin and reported under western blot images.